# Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG

> **NCT06981390** · NA · NOT_YET_RECRUITING · sponsor: **Kexiang Liu, MD** · enrollment: 300 (estimated)

## Conditions studied

- Coronary Artery Disease
- Coronary Artery Bypass Grafting
- Saphenous Vein
- Dual Antiplatelet Therapy

## Interventions

- **DRUG:** Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy)
- **DRUG:** Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy)
- **DRUG:** Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)

## Key facts

- **NCT ID:** NCT06981390
- **Lead sponsor:** Kexiang Liu, MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-02-20
- **Final completion:** 2027-03-20
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06981390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06981390, "Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06981390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*